Active substance
Barium sulfate
- US FDA 14
- WHO EML 1
- Safety 6
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| E-Z-HD | 98% | for suspension · oral | BRACCO | Prescription | 11 Jan 2016 |
| E-Z-PAQUE | 96% | for suspension · oral | BRACCO | Prescription | 11 Jan 2016 |
| VARIBAR THIN LIQUID | 81% | for suspension · oral | BRACCO | Prescription | 11 Jan 2016 |
| READI-CAT 2 | 2% | suspension · oral | BRACCO | Prescription | 15 Jan 2016 |
| READI-CAT 2 SMOOTHIE | 2% | suspension · oral | BRACCO | Prescription | 15 Jan 2016 |
| LIQUID E-Z-PAQUE | 60% | suspension · oral | BRACCO | Prescription | 15 Jan 2016 |
| VARIBAR NECTAR | 40% | suspension · oral | BRACCO | Prescription | 15 Jan 2016 |
| TAGITOL V | 40% | suspension · oral | BRACCO | Prescription | 15 Jan 2016 |
| VARIBAR THIN HONEY | 40% | suspension · oral | BRACCO | Prescription | 15 Jan 2016 |
| VARIBAR HONEY | 40% | suspension · oral | BRACCO | Prescription | 15 Jan 2016 |
| ENTERO VU 24% | 24% | suspension · oral | BRACCO | Prescription | 15 Jan 2016 |
| VARIBAR PUDDING | 40% | paste · oral | BRACCO | Prescription | 14 Oct 2016 |
| E-Z-DISK | 700MG | tablet · oral | BRACCO | Prescription | 1 Aug 2025 |
| E-Z-CAT DRY | 40% | for suspension · oral | BRACCO | Discontinued | 11 Jan 2016 |
WHO WHO Model List of Essential Medicines (2025)
- 14.2. Diagnostic agents > Radiocontrast media · core (EML); complementary (EMLc)
Barium sulfate with suspending agents
Oral > Liquid: Aqueous suspension
Safety signals and safety-related labeling changes
- US FDA 30 Apr 2019 E-Z-HD — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 26 Mar 2018 VARIBAR THIN HONEY — safety-related labeling change
Labeling sections changed: Use in Specific Populations - US FDA 4 Aug 2017 LIQUID E-Z-PAQUE — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Use in Specific Populations - US FDA 4 Aug 2017 TAGITOL V — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Use in Specific Populations - US FDA 8 Feb 2017 READI-CAT 2 — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 8 Feb 2017 READI-CAT 2 SMOOTHIES — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.